Takashi Nomiyama
Shizuoka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital-based claims database.
Journal: Journal of diabetes investigation
Published: March 27, 2026
Fingertip skin autofluorescence as a non-invasive marker for vascular complications in patients with type 2 diabetes.
Journal: Journal of diabetes investigation
Published: June 18, 2025
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: November 21, 2021
Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth.
Journal: Diabetology international
Published: April 21, 2021
Differential Effects of DPP-4 Inhibitors, Anagliptin and Sitagliptin, on PCSK9 Levels in Patients with Type 2 Diabetes Mellitus who are Receiving Statin Therapy.
Journal: Journal of atherosclerosis and thrombosis
Published: December 21, 2020
Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro.
Journal: Diabetology international
Published: October 07, 2020
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Effect of Anagliptin versus Sitagliptin on Inflammatory Markers: Sub-Analysis from the REASON Trial.
Journal: Diabetes, metabolic syndrome and obesity : targets and therapy
Published: September 20, 2020
Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus.
Journal: Frontiers in endocrinology
Published: June 23, 2020
Pemafibrate, a PPAR alpha agonist, attenuates neointima formation after vascular injury in mice fed normal chow and a high-fat diet.
Journal: Heliyon
Published: June 17, 2020
Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
Journal: Journal of atherosclerosis and thrombosis
Published: June 09, 2020
Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy.
Journal: Cardiovascular diabetology
Published: April 04, 2020
Last Updated: 09/26/2026